Skip main navigation
Close Drawer MenuOpen Drawer Menu
APA Publishing Logo

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
Letters to the EditorFull Access

Buprenorphine Issues

Published Online:4 Nov 2005https://doi.org/10.1176/pn.40.21.0039a

The two articles on buprenorphine treatment in the September 2 issue announced encouraging developments.

The article “Law Raises Patient Limits on Buprenorphine” reported the lifting of the cap of 30 patients who can receive buprenorphine treatment in a group practice at one time. The second article, “Support Offered for Buprenorphine Use,” announced that the Substance Abuse and Mental Health Services Administration, in collaboration with the American Society of Addiction Medicine, has introduced a support system for physicians who provide buprenorphine treatment.

I believe that a lot can be done to increase the awareness, knowledge, and competency of psychiatry residents with regard to buprenorphine treatment. Just recently WHO, for the first time, added both buprenorphine and methadone to the Model List of Essential Medicines.

APA and other psychiatric/addiction medicine organizations, in collaboration with the Accreditation Council for Graduate Medical Education and psychiatry residency programs, should take steps in encouraging the adoption of office-based buprenorphine training as a competency requirement for residents. The integrative model of dual-diagnosis treatment is seen as the most ideal and effective, and now that buprenorphine treatment is office based, I believe that competency in using this medication should be a requirement.

Albany, N.Y.
psychnewsPsychiatr NewsPsychiatric NewsNewspaper of the American Psychiatric AssociationPsychiatr NewsPsychiatr News0033-27041559-1255American Psychiatric Association
Deborah Hales, M.D., director of APA's Division of Education and Career Development, responds:4112005

APA fully supports buprenorphine-treatment training for psychiatry residents. As a first step to that end, APA's Council on Medical Education and Lifelong Learning recently voted to offer APA's buprenorphine course free to members-in-training (that is, residents who are APA members). We are now investigating the technology needed to make that happen. I will report further developments on the course and buprenorphine training for residents in a future issue.